Search EW
Edwards Lifesciences Corp
NYSE · CIK 1099800
Last close85.15
Daily change-0.04 (-0.05%)
10 Years gain+113.39%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
EW · STANDARD
SIC 3842 · Orthopedic, Prosthetic & Surgical Appliances & Supplies · Fiscal year end 1231
Fundamental
55.2Momentum
n/aAcceleration
n/aConfidence
83.0Annual Revenue18
Quarterly Revenue83
Annual CFO14
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth13.5 / 25
Quality11.7 / 25
Capital Efficiency12.2 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 1.7353%.
Key Metrics
Revenue Growth TTM17.25%OK
Revenue CAGR 3Y10.77%OK
Gross Margin77.69%OK
Operating Margin26.4%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC17.94%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-1.74%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $6.07B | $4.73B | $1.26B | $1.60B | $1.34B | 78.01% | 20.84% | 22% | 15.74% | 585.8M |
| 2025 FY Dec 31, 2024 | $5.44B | $4.32B | $1.38B | $542.30M | $289.90M | 79.46% | 25.35% | 5.33% | 20.32% | 599.3M |
| 2025 FY Dec 31, 2023 | $5.01B | $4.03B | $1.31B | $895.80M | $642.80M | 80.47% | 26.13% | 12.83% | 21.54% | 609.4M |
| 2024 FY Dec 31, 2022 | $4.46B | $3.74B | $1.50B | $1.22B | $973.60M | 83.79% | 33.57% | 21.81% | 25.72% | 624.2M |
| 2023 FY Dec 31, 2021 | $5.23B | $3.98B | $1.69B | $1.73B | $1.41B | 76.13% | 32.3% | 26.88% | 34.19% | 631.2M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $6.47B | sum latest 4 fiscal quarters Revenue | OK | 0001099800-26-000043, 0001099800-25-000062 |
| Revenue Growth TTM | 17.25% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001099800-26-000043, 0001099800-25-000062 |
| Revenue CAGR 3Y | 10.77% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001099800-26-000009 |
| Revenue CAGR 5Y | 6.7% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001099800-26-000009 |
| Gross Profit CAGR 3Y | 8.17% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001099800-26-000009 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001099800-26-000043, 0001099800-25-000062 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 77.69% | Gross Profit / Revenue | OK | 0001099800-26-000043, 0001099800-25-000062 |
| Operating Margin | 26.4% | Operating Income / Revenue | OK | 0001099800-26-000043, 0001099800-25-000062 |
| ROIC | 17.94% | NOPAT / Average Invested Capital | OK | 0001099800-26-000043, 0001099800-25-000062 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001099800-26-000043 |
| Current Ratio | 4.52x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 7.1x | (Cash + Short-term Investments) / Total Debt | OK | 0001099800-26-000043 |
| Revenue per Diluted Share | $11.21 | Revenue / Diluted Shares | OK | 0001099800-26-000043, 0001099800-25-000062 |